Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Radiomics Approach to Predict the Effect of Bevacizumab Plus Chemotherapy in Patients With Liver Metastases of Colorectal Cancer: A Prospective Multi-Centers Trial

NCT04213222 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT04213222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04213222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Radiomics Approach to Predict the Effect of Bevacizumab Plus Chemotherapy in Patients With Liver Metastases of Colorectal Cancer: A Prospective Multi-Centers Trial
Lead sponsor
Peking University People's Hospital
Phase
Observational
Overall status
Unknown status
Start date
October 31, 2020
Completion date
December 31, 2023
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer, liver metastases, rectal cancer